NAD+ is often discussed together with growth hormone-releasing compounds such as Tesamorelin and Sermorelin, as well as research peptides like Selank. While these compounds are frequently grouped into broad categories such as „longevity” or „biohacking,” from a scientific perspective they differ significantly from one another.
Their chemical structures, biological mechanisms, clinical evidence base, and regulatory status are not interchangeable. A reliable comparison should therefore be based on published studies for each compound rather than the marketing categories in which they are often grouped.
In this article, we compare NAD+ with peptide-based approaches such as Tesamorelin, examine whether these compounds have been studied together, and analyze the relative strength of the evidence supporting each approach.
How does NAD+ compare to peptide longevity compounds such as Tesamorelin?
The first significant difference is the chemical structure.
NAD+ is a dinucleotide composed of two nucleotide units joined together: one containing nicotinamide and the other containing adenine, linked by phosphate groups [1]. It is not a peptide.
Tesamorelin, Sermorelin, Selank, and other peptides are chains of amino acids linked by peptide bonds. Therefore, they belong to a fundamentally different category of molecules.
Tesamorelin is specifically a synthetic analogue of the human growth hormone-releasing hormone, or GHRH, composed of 44 amino acids.
Its structure contains a trans-3-hexenoic acid modification at the N-terminus. This modification helps protect the molecule from rapid enzymatic degradation and extends its circulation half-life compared to natural GHRH.
Tesamorelin works via a receptor-dependent hormonal mechanism.
It binds to GHRH receptors on pituitary somatotroph cells and activates G-protein coupled signaling. This stimulates the pituitary gland to release endogenous growth hormone.
Tesamorelin therefore does not supply growth hormone directly. Instead, it stimulates the body's own growth hormone secretion, maintaining a more physiological, pulsatile secretion pattern than the direct administration of exogenous growth hormone.
NAD+ works through a completely different biological system.
It acts as an electron-carrying coenzyme in cellular energy metabolism and is also an essential substrate for enzymes, including sirtuins and PARPs [1,2].
Both compounds therefore differ not only in structure, but also in their fundamental biological role: Tesamorelin acts through hormonal receptor signaling, whereas NAD+ participates directly in cellular metabolism and enzymatic activity.
Their clinical development history also differs significantly.
Tesamorelin was developed and studied for a specific medical problem: excess visceral adipose tissue associated with lipodystrophy in HIV-infected individuals.
Two large, multicenter, randomized, double-blind, placebo-controlled Phase 3 trials included a total of 806 HIV-infected individuals receiving antiretroviral therapy and having excess visceral adipose tissue in the abdomen. Participants were randomized in a 2:1 ratio to receive either tesamorelin 2 mg daily or placebo [3].
The initial 26-week study included 412 participants and showed that tesamorelin significantly reduced visceral adipose tissue compared with placebo. A moderate improvement in triglyceride levels and trunk fat was also observed [3].
A combined analysis of key studies showed that the reduction in visceral adipose tissue could be maintained for up to 52 weeks with continued treatment. Subcutaneous abdominal adipose tissue was preserved, and additionally, improvements in body image and lipid parameters were observed without clinically significant changes in glycemic parameters [3,4].
NAD+ precursors have undergone a much broader, but more exploratory, research path.
Instead of developing them for one clearly defined indication, NR, NMN, and other approaches related to NAD+ have been studied in areas such as energy metabolism, lipid profile, blood pressure, physical performance, Parkinson's disease, and peripheral artery disease [5,6].
However, this broader research program did not lead to an FDA-approved indication comparable to tesamorelin's specific approval in HIV-associated lipodystrophy.
Are NAD+ and GHRH analogue peptides sometimes combined?
NAD+ and GHRH-related compounds, such as Tesamorelin or Sermorelin, are sometimes offered together by longevity, wellness, or peptide clinics.
NAD+ can be administered intravenously or by injection, while the peptide component is part of a broader protocol involving several compounds. Such combinations are often presented in the context of cellular health, biohacking, longevity, or body optimization.
However, clinical practice and commercial availability must be distinguished from evidence derived from controlled clinical trials.
No published, controlled clinical trial has been identified that specifically tests NAD+ together with Tesamorelin as a single intervention.
Similarly, no dedicated study of the combination of NAD+ with Sermorelin or another GHRH analogue has been identified.
Claims that the combination of these compounds provides a specific synergistic effect are therefore not currently based on direct data from studies on such a combination.
Both classes of compounds indeed have different mechanisms of action.
GHRH analogues act through receptor-mediated hormonal signaling involving the pituitary gland and the growth hormone axis, whereas NAD+ participates in cellular energy metabolism and NAD+-dependent enzyme systems.
The lack of obvious mechanism overlap proves neither a harmful interaction nor a beneficial synergy.
It merely means that the compounds interact via different biological pathways, while the clinical effects of their simultaneous use remain insufficiently studied.
This situation is similar to other combinations of NAD+ with compounds such as NAC, berberine, resveratrol, or omega-3 fatty acids, where there are distinct biological rationales, but dedicated human combination studies are limited or lacking.
Which approach currently has stronger research support?
The answer depends on the specific effect being evaluated.
Regarding the FDA-approved indication, tesamorelin has a significantly stronger evidence base than NAD+.
Tesamorelin received FDA approval in 2010 specifically for reducing excess visceral adipose tissue in adults with HIV-associated lipodystrophy.
The approval was based on two large, multicenter, randomized, double-blind, placebo-controlled Phase 3 trials involving a total of 806 participants, along with safety data and data from extension studies up to 52 weeks [3,4].
Additional post-hoc analyses and observational studies evaluated metabolic and cardiovascular outcomes in the same clinical population [7].
This constitutes a mature, FDA-assessed clinical evidence package for one clearly defined indication.
No NAD+-related supplement or therapy has achieved a comparable body of evidence leading to FDA indication approval.
However, apart from the approved use of tesamorelin, the comparison looks different.
Tesamorelin is sometimes discussed or used outside of HIV-associated lipodystrophy for purposes such as general body composition improvement, anti-aging effects, or other longevity-related goals.
Such uses are off-label and are not supported by the same body of evidence that led to the approval of the drug for its official indication.
A systematic review evaluating therapies acting on the growth hormone axis in HIV-associated lipodystrophy indicated that placebo-controlled data for these interventions focus primarily on the HIV lipodystrophy population in which they were studied [8].
Strong evidence regarding tesamorelin in this population should therefore not be automatically extended to general claims regarding anti-aging or body composition in individuals without HIV-associated lipodystrophy.
NAD+ precursors have a different evidence profile.
It was evaluated in a broader range of randomized, placebo-controlled trials involving general adult populations and several specific clinical groups.
For example, a 60-day NMN study with varying doses involving 80 healthy middle-aged and older individuals showed a dose-dependent increase in NAD+ and an improvement in the 6-minute walk test score [5].
A meta-analysis of 40 human studies involving 14,750 participants showed that NAD+ precursors significantly reduced triglyceride, total cholesterol, and LDL cholesterol levels [6].
These results do not establish an approved medical indication for NAD+ precursors, but they show that NAD+-related research encompasses a broader range of metabolic and physical fitness outcomes in the general population than the evidence supporting the off-label use of Tesamorelin.
This distinction is therefore important.
For the specific approved medical use, Tesamorelin has a much stronger evidence base, but it applies specifically to HIV-associated lipodystrophy.
For broader exploratory studies regarding metabolic outcomes and physical fitness in the general adult population, NAD+ precursors have a larger and more diverse human research base, although without an FDA-approved indication.
Regarding broad claims of anti-life or life-extension, none of these categories currently have strong direct evidence from human studies supporting the extension of human lifespan or a proven general anti-aging effect.
How do these approaches differ in terms of their intended effect?
NAD+ and Tesamorelin are not directly competing versions of the same intervention.
Their biological mechanisms, regulatory status, studied populations, and assessed clinical outcomes differ significantly, which is why a simple comparison of the two compounds is less useful than comparing the quality of evidence for a specific purpose.
For HIV-associated lipodystrophy, Tesamorelin has an FDA-approved indication supported by controlled Phase 3 trials [3,4].
Clinical studies have also shown that the reduction in visceral adipose tissue depended on the continuation of treatment. After discontinuation of tesamorelin, the amount of visceral adipose tissue increased again, indicating that the effect was not a permanent change achieved after a single treatment cycle [3,4].
For general body composition, energy, or anti-aging applications in individuals without HIV-associated lipodystrophy, Tesamorelin is used off-label.
Evidence supporting such broader uses is much less established than data concerning its approved use [8].
Research on NAD+ precursors concerns a different set of results.
They evaluated NAD+ biomarkers, lipid parameters, energy metabolism, physical fitness, and selected issues in specific disease states [5,6].
In this category, oral NR and NMN currently have a larger base of human clinical trials than many direct NAD+ delivery methods.
Combining NAD+ with Tesamorelin presents yet another issue.
Because both compounds operate via different mechanisms, they can be treated as two separate interventions placed in the same protocol, rather than as different elements of a single established pharmacological therapy.
No dedicated combination study has shown that using them together provides a greater effect than using each of them independently.
Based on current evidence, such a combination should therefore not be described as a clinically validated „longevity stack” or an established synergistic protocol.
How do NAD+ and other peptides fit into this comparison?
Tesamorelin is particularly useful for comparison because it has undergone extensive clinical development and has an FDA-approved indication.
Other peptides often grouped together with NAD+ in the „longevity” or „biohacking” category may have a completely different level of evidence.
Sermorelin, for example, is also related to the growth hormone-releasing hormone pathway and acts via GHRH receptors, which is why mechanistically it is much closer to Tesamorelin than to NAD+.
Research peptides such as Selank belong to another, distinct category and should not be assumed to have the same mechanism, clinical evidence base, or regulatory status as NAD+ or GHRH analogues.
Grouping these compounds together under a broad commercial category can therefore obscure important scientific differences.
The term „peptide” describes a structural class rather than a single common mechanism of action. Different peptides can interact with completely different receptors and biological systems.
NAD+ does not belong to this structural category at all.
For this reason, comparisons between NAD+ and peptides are most useful when they focus on specific mechanisms, clinical outcomes, research quality, and regulatory status, rather than treating all compounds advertised in the context of longevity as interchangeable.
Comparison of the strength of evidence
The hierarchy of evidence varies significantly depending on the context and the specific claim.
Tesamorelin has strong data from randomized Phase 3 trials for a narrow, clearly defined clinical indication and has undergone formal FDA evaluation for this use [3,4].
Its evidence base becomes considerably weaker when claims extend beyond HIV-associated lipodystrophy to general anti-aging, longevity, or body composition in populations not represented in key studies [8].
NAD+ precursors do not have a comparable approved indication, but they have been studied in a broader range of populations and outcomes.
This creates a different kind of evidence base: broader and more exploratory, but less conclusive for a single medical indication.
Other research peptides may have an even narrower evidence base, depending on the specific compound.
The fact that NAD+, Tesamorelin, Sermorelin, Selank, and other compounds appear together in longevity clinics or online discussions does not mean that the quality of the evidence supporting them is comparable.
Clinical evidence remains specific to the particular compound and the specific evaluated effect.
Limitations of current evidence
- The strongest evidence regarding tesamorelin specifically relates to its FDA-approved indication for reducing excess visceral adipose tissue in HIV-infected adults with lipodystrophy. Evidence for off-label uses, such as general anti-aging, cognitive effects, or body composition in HIV-negative individuals, is significantly less established [8].
- No dedicated clinical trials testing NAD+ together with Tesamorelin, Sermorelin, or other GHRH analogue peptides have been identified.
- Research into NAD+ precursors encompasses a broader range of outcomes than Tesamorelin's narrow approved indication, but has not led to an FDA-approved medical indication for NAD+-related supplementation or therapy.
- It has been shown that the reduction in visceral adipose tissue observed during treatment with tesamorelin reverses after discontinuation of treatment, meaning that the key evidence describes an effect associated with the continuation of therapy rather than a permanent one-time change [3,4].
- The comparison concerns broad classes of compounds. Individual products, formulations, and doses may vary significantly in terms of manufacturing standards, source, regulatory oversight, and quality, particularly in the case of compounded preparations or peptides sourced from unregulated or less regulated channels outside the system of FDA-approved products.
Disclaimer
The article is strictly educational in nature and summarizes scientific research. It does not constitute medical advice or a recommendation for or against the use of NAD+, Tesamorelin, Sermorelin, Selank, or other peptide-based interventions.
NAD+ and its precursors should not be presented as FDA- or EMA-approved methods for preventing, treating, or curing diseases, unless referring to a specific approved medicinal product and indication.
Tesamorelin, sold under the brand names Egrifta and Egrifta WR, is FDA-approved specifically for reducing excess visceral adipose tissue in adults with HIV-associated lipodystrophy. Uses beyond this approved indication are off-label and should not be presented as having the same level of evidence or the same regulatory status as the approved use. Grouping NAD+, Tesamorelin, or other peptides in the same commercial longevity or biohacking category does not imply comparable mechanisms of action, efficacy, safety, regulatory status, or quality of evidence.
References
[1] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[2] Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x
[3] Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
[4] Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
[5] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[6] Zhong, O., Wang, J., Tan, Y., Lei, X., & Tang, Z. (2022). Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: A meta-analysis. Nutrition & Metabolism, 19, 20. https://doi.org/10.1186/s12986-022-00653-9
[7] Falutz, J., Potvin, D., Mamputu, J. C., Assaad, H., Zoltowska, M., Michaud, S. E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322. https://doi.org/10.1097/QAI.0b013e3181cbdaff
[8] Sivakumar, T., Mechanic, O., Fehmie, D. A., & Paul, B. (2011). Growth hormone axis treatments for HIV-associated lipodystrophy: A systematic review of placebo-controlled trials. HIV Medicine, 12(8), 453–462. https://doi.org/10.1111/j.1468-1293.2010.00906.x